Hotlist highlights: Surging on financial wins and new treatments

In partnership with

Good day, 360!

Here are some of our top movers today. And please join Jeff Williams LIVE today for his PRE-MARKET scan in Market Masters from 9-11AM today (complimentary access in effect). Be the best prepared trader on the Street🔥.

FOCUS LIST🔎

SURG - Up over 79% in the pre-market after issuing revenue guidance of over $200 million in the next 12 months

THTX - Up over 37% in pre after announcing FDA approval for EGRIFTA WR™ (Tesamorelin F8) to treat excess visceral abdominal fat in adults with HIV and Lipodystrophy 

CISO - Up over 15% in pre after announcing it has payed off highest-interest debt, extends $7M in convertible notes   

HOTLIST🔥

SURG - Up over 79% in the pre-market after issuing revenue guidance of over $200 million in the next 12 months 

SurgePays Inc. (SURG) together with its subsidiaries, operates as a financial technology and telecom company in the United States.

In the after-hours yesterday, the company announced its financial results for the year ended December 31, 2024, and issued guidance of over $200 million in revenue over the next 12 months and positive cash flow from operations before the end of 2025, following the successful integration and official launch with AT&T.

This guidance is based solely on the monetization of core MVNO and POS platforms already deployed. As these platforms scale — both through direct customer acquisition and wholesale MVNE relationships — we anticipate expanding both revenue and margins.

Shares of SURG traded up over 79% in the pre-market in reaction to the news.

The $2.35 area has acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $2.65, $2.80 and then the pre-market high at $2.97. Beyond that, $3.30, $3.40 and $4 come into play.

Below $2.35, targets to the downside are $2.30, $2, $1.70 and then a gap fill at $1.38.

THTX - Up over 37% in pre after announcing FDA approval for EGRIFTA WR™ (Tesamorelin F8) to treat excess visceral abdominal fat in adults with HIV and Lipodystrophy  

Theratechnologies Inc. (THTX) is a biopharmaceutical company that focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.

In the after-hours yesterday, the company announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection. The Company will commercialize the new formulation under the tradename EGRIFTA WR™.

Tesamorelin for injection is the only medication approved in the U.S. for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. The new formulation, EGRIFTA WR™, is a daily injectable but only needs weekly reconstitution. It requires less than half the administration volume as the current F4 formulation, sold in the U.S. as EGRIFTA SV®, which is reconstituted daily.  

Shares of THTX traded up over 37% in the pre-market in reaction to the results.

The $2.06 area acted as support in the after-hours and pre-market and will be an important level to watch.

Above it, targets to the upside are $2.20, $2.40, $2.95 and then the pre-market high at $3.07. Beyond that, $3.30 and $4 come into  play.

Below $2.06, targets to the downside are $1.80, $1.65 and then a gap fill at $1.54.

CISO - Up over 15% in pre after announcing it has payed off highest-interest debt, extends $7M in convertible notes 

CISO Global Inc. (CISO) operates as a cybersecurity and compliance company in the United States, Chile, and internationally. 

In the after-hours yesterday, the company announced it has successfully paid off its highest-interest loans as part of its ongoing efforts to strengthen its balance sheet and improve operational efficiency.

To further financial stability, CISO Global has also secured extensions on convertible notes totaling $7 million. These notes are held by long-standing partners with close relationships with the company, reflecting continued confidence in the long-term vision and stability of the business.

“Clearing the company’s highest-interest debt removes a significant obstacle to our growth,” said Deb Smith, Chief Financial Officer of CISO Global. “With this burden lifted, we’ve improved our cash flow, giving us the flexibility to accelerate our shift into a more profitable, software-first business model.”

Shares of CISO traded up over 15% in the pre-market in reaction to the news.

The $0.46 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $0.50, $0.56, $0.62, $0.64 and then the pre-market high at $0.67. Beyond that, $0.77, $0.90 and $1 come into play.

Below $0.46, targets to the downside are $0.4260, $0.37 and $0.3255.

MARKET NEWS 📰